Stock Events

Stock Events

Cingulate 

$6.21
33
+$0.37+6.34% Tuesday 20:00

Statistics

Day High
6.28
Day Low
5.78
52W High
11.89
52W Low
3.2
Volume
369,850
Avg. Volume
474,821
Mkt Cap
41.96M
P/E Ratio
0.03
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-5.64
-3.92
-2.2
-0.48
Expected EPS
-0.48
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-31.09MNet Income

Analyst Ratings

$36.00Average Price Target
The highest estimate is 58.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CING. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Supernus Pharmaceuticals
SUPN
Mkt Cap3.12B
Supernus Pharmaceuticals has a portfolio including ADHD treatments, competing in the same market as Cingulate.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Takeda Pharmaceutical Company offers a range of ADHD medications, making it a direct competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, offers ADHD medications, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap237.61B
Novartis AG provides medications for ADHD, making it a competitor in the same treatment category.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a diverse portfolio that includes treatments for neurological disorders, potentially competing in the ADHD space.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company has been involved in psychiatric and neurological treatments, potentially competing with Cingulate's ADHD focus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a broad portfolio that includes CNS treatments, indirectly competing with Cingulate.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. focuses on innovative therapies, including for neurological conditions, potentially putting it in competition with Cingulate.

About

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Show more...
CEO
Mr. John A. Roberts M.B.A.
Employees
13
Country
US
ISIN
US17248W3034

Listings

XNAS
US
CING
XNAS
US
CINGW
BOATS
BOATS
CING.BOATS

0 Comments

Share your thoughts

FAQ

What is Cingulate stock price today?▼
The current price of CING is $6.21 USD — it has increased by +6.34% in the past 24 hours. Watch Cingulate stock price performance more closely on the chart.
What is Cingulate stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cingulate stocks are traded under the ticker CING.
Is Cingulate stock price growing?▼
CING stock has fallen by -2.36% compared to the previous week, the month change is a -0.96% fall, over the last year Cingulate has showed a +46.12% increase.
What is Cingulate market cap?▼
Today Cingulate has the market capitalization of 41.96M
When is the next Cingulate earnings date?▼
Cingulate is going to release the next earnings report on May 13, 2026.
What were Cingulate earnings last quarter?▼
CING earnings for the last quarter are -0.96 USD per share, whereas the estimation was -0.63 USD resulting in a -51.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cingulate revenue for the last year?▼
Cingulate revenue for the last year amounts to 0 USD.
What is Cingulate net income for the last year?▼
CING net income for the last year is -31.09M USD.
How many employees does Cingulate have?▼
As of April 01, 2026, the company has 13 employees.
In which sector is Cingulate located?▼
Cingulate operates in the Health Care sector.
When did Cingulate complete a stock split?▼
The last stock split for Cingulate was on August 09, 2024 with a ratio of 1:12.
Where is Cingulate headquartered?▼
Cingulate is headquartered in Kansas City, US.